Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | SNCA | P37840 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29402769 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL9975753 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL29358434 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Coenzyme Q4 SCHEMBL6279408 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL13026488 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL11901691 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL19858 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL16393869 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL5530210 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Coenzyme Q4 SCHEMBL6279406 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 349 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735052-A1 | PROMOTERS | Purespring Therapeutics Limited (GB) | 2026-05-06 | — | — | EP | claimed |
| EP-4735053-A1 | REGULATORY ELEMENTS | Purespring Therapeutics Limited (GB) | 2026-05-06 | — | — | EP | claimed |
| CN-121573821-A | Sewage biological treatment promoter and preparation method and application thereof | 云南合续环境科技股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| EP-4689135-A1 | PROMOTER | Purespring Therapeutics Limited (GB) | 2026-02-11 | — | — | EP | claimed |
| US-12544460-B2 | AAV gene therapy for treating nephrotic syndrome | THE UNIVERSITY OF BRISTOL (GB) | 2026-02-10 | — | — | US | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4618872-A1 | METHODS OF DELIVERING A VIRAL VECTOR TO A KIDNEY | The University of Bristol (GB) | 2025-09-24 | — | — | EP | claimed |
| US-20250262169-A1 | METHODS OF TREATING COENZYME Q10 DEFICIENCY | THLIVERIS, ANDREW T. | 2025-08-21 | — | — | US | claimed |
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| CN-113543814-B | AAV gene therapy for the treatment of nephrotic syndrome | 布里斯托尔大学 | 2025-06-17 | — | — | CN | claimed |
| WO-2023031479-A1 | AN IN VITRO METHOD FOR DIAGNOSIS FOR ISCHEMIC VASCULAR DISEASES AND RELATED COMPLICATIONS | PROSTEM CARDIOLOGY B.V. (NL) | 2023-03-09 | — | — | WO | claimed |
| EP-4144864-A1 | AN IN VITRO METHOD FOR DIAGNOSIS FOR ISCHEMIC VASCULAR DISEASES AND RELATED COMPLICATIONS | Prostem Cardiology B.V. (NL) | 2023-03-08 | — | — | EP | claimed |
| US-20220364178-A1 | URINARY RNA SIGNATURES IN RENAL CELL CARCINOMA (RCC) | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-11-17 | — | — | US | claimed |
| US-11485743-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | claimed |
| US-20220325301-A1 | AUXOTROPHIC SELECTION METHODS | AUXOLYTIC LTD (GB) | 2022-10-13 | — | — | US | claimed |
| EP-4013514-A1 | URINARY RNA SIGNATURES IN RENAL CELL CARCINOMA (RCC) | University Of Massachusetts (US) | 2022-06-22 | — | — | EP | claimed |
| US-20220125950-A1 | AAV GENE THERAPY FOR TREATING NEPHROTIC SYNDROME | THE UNIVERSITY OF BRISTOL (GB) | 2022-04-28 | — | — | US | claimed |
| WO-2022073994-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | MERCK PATENT GMBH (DE) | 2022-04-14 | — | — | WO | claimed |
| EP-3966339-A1 | AUXOTROPHIC SELECTION METHODS | Auxolytic Ltd (GB) | 2022-03-16 | — | — | EP | claimed |
| WO-2022050763-A1 | BIOMARKER FOR DIAGNOSIS OF PRIMARY INTRAOCULAR LYMPHOMA AND USE THEREOF | 재단법인 아산사회복지재단 | 2022-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485743-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | LMNA 2563/4885MAOB 2702/4885PTGS1 4442/4885 |
| US-12544460-B2 | AAV gene therapy for treating nephrotic syndrome | NUP93, ANKRD52, RBM25 | LMNA 1262/4885MAOB 4478/4885PTGS1 4543/4885 |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | REN, AGT, FRS2 | LMNA 3826/4885MAOB 3772/4885PTGS1 910/4885 |
| US-20250262169-A1 | METHODS OF TREATING COENZYME Q10 DEFICIENCY | NDUFB10, NDUFA10, NDUFB11 | LMNA 1283/4885MAOB 664/4885PTGS1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.